Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

January 4, 2024

https://www.globenewswire.com/news-release/2024/01/04/2804309/0/en/Werewolf-Therapeutics-Appoints-Michael-Atkins-M-D-to-its-Board-of-Directors.html

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq:HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.

Read more at globenewswire.com

Related news for (HOWL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.